female patients who are currently pregnant history of severe allergic reaction to vaccines concomitant inherited immunodeficiency any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator s opinion, could compromise the subject s safety or put the study outcomes at undue risk. receive cytotoxic chemotherapy within 2 weeks prior to vaccination receive intravenous immunoglobulin (ivig) within 2 months prior to vaccination receive anti-cd20 and/or anti-cd19 monoclonal antibody therapy within 6 months prior to vaccination receive cellular therapy (e.g. car-t cells) within 12 months prior to vaccination history of allogeneic stem cell transplantation

female patients who are currently pregnant history of severe allergic reaction to vaccines concomitant inherited immunodeficiency any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator s opinion, could compromise the subject s safety or put the study outcomes at undue risk. receive cytotoxic chemotherapy within 2 weeks prior to vaccination receive intravenous immunoglobulin (ivig) within 2 months prior to vaccination receive anti-cd20 and/or anti-cd19 monoclonal antibody therapy within 6 months prior to vaccination receive cellular therapy (e.g. car-t cells) within 12 months prior to vaccination history of allogeneic stem cell transplantation

None

None

female patients who are currently pregnant history of severe allergic reaction to vaccines concomitant inherited immunodeficiency any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator s opinion, could compromise the subject s safety or put the study outcomes at undue risk. receive cytotoxic chemotherapy within 2 weeks prior to vaccination receive intravenous immunoglobulin (ivig) within 2 months prior to vaccination receive anti-cd20 and/or anti-cd19 monoclonal antibody therapy within 6 months prior to vaccination receive cellular therapy (e.g. car-t cells) within 12 months prior to vaccination history of allogeneic stem cell transplantation

female patients who are currently pregnant history of severe allergic reaction to vaccines concomitant inherited immunodeficiency any life-threatening illness, medical condition, or organ system dysfunction that, in the investigator s opinion, could compromise the subject s safety or put the study outcomes at undue risk. receive cytotoxic chemotherapy within 2 weeks prior to vaccination receive intravenous immunoglobulin (ivig) within 2 months prior to vaccination receive anti-cd20 and/or anti-cd19 monoclonal antibody therapy within 6 months prior to vaccination receive cellular therapy (e.g. car-t cells) within 12 months prior to vaccination history of allogeneic stem cell transplantation